EGEN, Inc., is a clinical stage biopharmaceutical company focused on developing nucleic acid-based therapeutics for cancer and other difficult to treat diseases using proprietary nanoparticle delivery systems. The company's synthetic biocompatible delivery vehicles can be used to deliver therapeutic genes, inhibitory RNA and small molecules by protecting the therapeutic cargo from degradation, promoting uptake by target cells and facilitating intracellular trafficking. The primary activities of the company are the application of the TheraPlas™ and TheraSilence™ platforms to the treatment of human disease. EGEN's lead candidate, EGEN-001, is currently in Phase II clinical testing for ovarian cancer and in Phase I clinical testing for colorectal cancer.